IGC Pharma
About: IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Employees: 67
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
700% more call options, than puts
Call options by funds: $8K | Put options by funds: $1K
350% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 2
3% more capital invested
Capital invested by funds: $1.11M [Q2] → $1.14M (+$30.2K) [Q3]
0.36% more ownership
Funds ownership: 3.83% [Q2] → 4.2% (+0.36%) [Q3]
4% less funds holding
Funds holding: 24 [Q2] → 23 (-1) [Q3]
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Ascendiant Capital Edward Woo 36% 1-year accuracy 26 / 73 met price target | 983%upside $4 | Buy Maintained | 5 Dec 2024 |
Financial journalist opinion
Based on 3 articles about IGC published over the past 30 days
